title: Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study.
abstract: OBJECTIVE
  To assess the incidence and progression of macular atrophy and other key anatomic outcomes over 7 to 8 years in an early cohort of ranibizumab-treated exudative age-related macular degeneration patients.
  
  
  METHODS
  Follow-up analysis of long-term outcomes in a multicenter treatment cohort.
  
  
  METHODS
  Fourteen study sites enrolled 65 previous subjects from the ranibizumab treatment arms of the ANCHOR, MARINA, and HORIZON trials. In a single update visit, clinical assessment and retinal imaging studies were performed, with comparison with each subject's prior results from the previous trials. Early Treatment Diabetic Retinopathy Study visual acuity was the primary outcome. Secondary outcomes, including area of macular atrophy and selected anatomic factors, were analyzed for associations with long-term vision outcomes.
  
  
  RESULTS
  At a mean 7.3 years after ANCHOR or MARINA enrollment, mean visual acuity was 54 letters, study eyes having received a mean 1.6 injections per year since the HORIZON study. Macular atrophy was present in 98% of study eyes, the mean area increasing from 0.83 ± 0.96 mm(2) at the ANCHOR or MARINA year 2 exit to 2.22 ± 1.6 mm(2) at the SEVEN-UP visit, a growth rate of 0.28 mm(2)/year. Progression of macular atrophy was associated significantly with visual decline over this 5-year period (P < .001), and final macular atrophy lesion size was related significantly to final vision (P < .001). Other key anatomic outcomes (macular thickening, thinning, or fluid and submacular fibrosis) did not have significant effects on vision outcomes.
  
  
  CONCLUSIONS
  Seven years after initiation of intensive ranibizumab therapy for exudative age-related macular degeneration, macular atrophy progression and severity were the primary anatomic determinants of visual outcomes.
authors: Department of Ophthalmology, University of California, San Francisco, San Francisco, California. Electronic address: BhisitkulR@vision.ucsf.edu.
authors: Robert B
authors: RB
authors: Bhisitkul
authors: Department of Ophthalmology, University of California, San Francisco, San Francisco, California.
authors: Thais S
authors: TS
authors: Mendes
authors: Department of Ophthalmology, University of California, San Francisco, San Francisco, California.
authors: Soraya
authors: S
authors: Rofagha
authors: Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.
authors: Wayne
authors: W
authors: Enanoria
authors: Retina-Vitreous Associates, Los Angeles, California.
authors: David S
authors: DS
authors: Boyer
authors: Doheny Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
authors: SriniVas R
authors: SR
authors: Sadda
authors: Shiley Eye Center, University of California, San Diego, La Jolla, California.
authors: Kang
authors: K
authors: Zhang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D057092:Geographic Atrophy / Q000175:diagnosis* / Q000503:physiopathology; D006801:Humans; D015994:Incidence; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology*; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab